rs151315725
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_001159699.2(FHL1):c.871G>A(p.Asp291Asn) variant causes a missense change. The variant allele was found at a frequency of 0.0163 in 1,208,769 control chromosomes in the GnomAD database, including 140 homozygotes. There are 6,223 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Consequence
NM_001159699.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FHL1 | ENST00000370683.6 | c.871G>A | p.Asp291Asn | missense_variant | Exon 6 of 6 | 1 | NM_001159699.2 | ENSP00000359717.1 | ||
FHL1 | ENST00000394155.8 | c.*51G>A | 3_prime_UTR_variant | Exon 8 of 8 | 5 | NM_001159702.3 | ENSP00000377710.2 |
Frequencies
GnomAD3 genomes AF: 0.0115 AC: 1274AN: 110492Hom.: 9 Cov.: 22 AF XY: 0.0101 AC XY: 329AN XY: 32716
GnomAD3 exomes AF: 0.0109 AC: 1994AN: 183528Hom.: 17 AF XY: 0.0113 AC XY: 765AN XY: 67958
GnomAD4 exome AF: 0.0167 AC: 18390AN: 1098222Hom.: 131 Cov.: 33 AF XY: 0.0162 AC XY: 5895AN XY: 363582
GnomAD4 genome AF: 0.0115 AC: 1272AN: 110547Hom.: 9 Cov.: 22 AF XY: 0.0100 AC XY: 328AN XY: 32781
ClinVar
Submissions by phenotype
not specified Benign:6
Variant summary: FHL1 c.*51G>A is located in the untranslated mRNA region downstream of the termination codon. The variant allele was found at a frequency of 0.011 in 183528 control chromosomes in the gnomAD database, including 17 homozygotes. The observed variant frequency is approximately 28 fold of the estimated maximal expected allele frequency for a pathogenic variant in FHL1 causing Emery-Dreifuss Muscular Dystrophy phenotype (0.00039), strongly suggesting that the variant is benign. To our knowledge, no occurrence of c.*51G>A in individuals affected with Emery-Dreifuss Muscular Dystrophy and no experimental evidence demonstrating its impact on protein function have been reported. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as benign. Based on the evidence outlined above, the variant was classified as benign. -
- -
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
- -
- -
- -
not provided Benign:5
- -
- -
- -
- -
- -
X-linked myopathy with postural muscle atrophy Benign:1
- -
Cardiovascular phenotype Benign:1
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at